Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 08, 2013 08:30 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics to Present at Two August Investor Conferences

CRANBURY, N.J., Aug. 8, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at two...
August 08, 2013 08:00 ET | Source: Novavax, Inc.

Novavax Reports Second-Quarter 2013 Financial Results

ROCKVILLE, Md., Aug. 8, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company creating novel recombinant nanoparticle vaccines to address a broad range of...
August 08, 2013 07:45 ET | Source: BG Medicine, Inc.

BG Medicine Reports 2013 Second Quarter Financial Results and Provides Second Half Outlook

Focusing Investments on Increasing U.S. and EU Galectin-3 Adoption 2013 Financial and Operational Guidance Provided WALTHAM, Mass., Aug. 8, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc....
August 08, 2013 07:00 ET | Source: Response Genetics, Inc.

Response Genetics, Inc. Announces Second Quarter 2013 Financial Results

LOS ANGELES, Aug. 8, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's...
August 08, 2013 03:50 ET | Source: Topotarget

Spectrum Pharmaceuticals announces postponement in filing of NDA for belinostat in PTCL to Q4 2013

To NASDAQ OMX Copenhagen A/S Announcement no. 20-13 / Copenhagen, August 8, 2013 On August 7, 2013, Spectrum Pharmaceuticals announced that the filing of the New Drug Application (NDA) for...
August 07, 2013 17:00 ET | Source: Immune Pharmaceuticals Inc

EpiCept Stockholders Overwhelmingly Approve Final Conditions to Merger with Immune Pharmaceuticals Ltd.

Almost 92% of Votes Cast in Favor of Proposals Merger Expected to close in August 2013 TARRYTOWN, N.Y., Aug. 7, 2013 /PRNewswire/ -- EpiCept Corporation (Nasdaq and Nasdaq...
August 07, 2013 16:05 ET | Source: Aastrom Biosciences, Inc.

Aastrom Biosciences Reports Second-Quarter and First-Half 2013 Financial Results

ANN ARBOR, Mich., Aug. 7, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
August 07, 2013 16:05 ET | Source: StemCells, Inc.

StemCells, Inc. Reports Second Quarter 2013 Financial Results and Provides Business Update

NEWARK, Calif., Aug. 7, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem...
August 07, 2013 16:01 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Second Quarter 2013 Financial Results

Full-Year 2013 Net Cash Spend Guidance Reduced to $47 Million to $53 Million – Current Cash Expected to Fund Operations into 4Q14 Multiple Next-Generation Enzyme Replacement Therapies...
August 07, 2013 16:01 ET | Source: XOMA Royalty Corporation

XOMA Highlights Recent Achievements and Reports Financial Results for Second Quarter 2013

BERKELEY, Calif., Aug. 7, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today reported its operational highlights and...